Pages

Showing posts with label Qsymia. Show all posts
Showing posts with label Qsymia. Show all posts

November 14, 2012

European regulators won’t recommend weight loss drug containing Topamax ingredient

The European Medicines Agency (EMA) has recommended not to approve a new weight loss drug containing topiramate, the active drug in Topamax. The EMA expressed concerns about the long-term risks of cardiovascular problems and other side effects associated with the drug, known as Qsymia. Topamax was recently upgraded to the FDA’s Pregnancy Category D, signifying the drug has a proven risk of causing birth defects.

Read more about the risks associated with Qsymia...